Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Entecavir
Drug ID BADD_D00774
Description Entecavir is an oral antiviral drug used in the treatment of hepatitis B infection. It is marketed under the trade name Baraclude (BMS). Entecavir is a guanine analogue that inhibits all three steps in the viral replication process, and the manufacturer claims that it is more efficacious than previous agents used to treat hepatitis B (lamivudine and adefovir). It was approved by the U.S. Food and Drug Administration (FDA) in March 2005.
Indications and Usage For the treatment of chronic hepatitis B virus infection in adults with evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease.
Marketing Status Prescription
ATC Code J05AF10
DrugBank ID DB00442
KEGG ID D04008
MeSH ID C413685
PubChem ID 135398508
TTD Drug ID D0KR2J
NDC Product Code 42291-261; 31722-833; 69097-425; 60050-057; 43547-437; 16729-389; 60687-216; 51991-895; 42291-262; 0003-1614; 42806-659; 65862-842; 50268-289; 71921-194; 0003-1611; 63285-888; 63285-887; 68382-921; 65862-798; 70771-1020; 42806-658; 51407-065; 51991-896; 16714-718; 68382-920; 16729-388; 71921-195; 62227-101; 53104-7692; 31722-834; 16714-717; 65862-841; 0003-1612; 13612-0020; 70771-1019; 65977-0086; 62227-102; 69097-426; 51407-064; 17381-031; 66406-0331; 60050-077; 76397-001; 65162-446; 65162-449; 43547-436
Synonyms entecavir | Baraclude
Chemical Information
Molecular Formula C12H15N5O3
CAS Registry Number 142217-69-4
SMILES C=C1C(CC(C1CO)O)N2C=NC3=C2N=C(NC3=O)N
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Cardiac failure02.05.01.0010.009771%
Cardio-respiratory arrest22.02.06.007; 02.03.04.0020.014982%Not Available
Cataract06.06.01.0010.014982%
Cerebral haemorrhage24.07.04.001; 17.08.01.0030.011725%Not Available
Cerebral infarction17.08.01.004; 24.04.06.0020.014982%Not Available
Cerebrovascular accident24.03.05.001; 17.08.01.007--
Chest discomfort08.01.08.019; 02.02.02.009; 22.02.08.001--Not Available
Chest pain22.02.08.003; 08.01.08.002; 02.02.02.011--Not Available
Chills15.05.03.016; 08.01.09.001--
Coma hepatic17.02.09.002; 09.01.03.0050.003908%Not Available
Cough22.02.03.001--
Deafness04.02.01.0010.022473%Not Available
Death08.04.01.0010.087938%
Dementia17.03.01.001; 19.20.02.0010.014982%Not Available
Depression19.15.01.001--
Dermatitis23.03.04.002--Not Available
Diabetes mellitus14.06.01.001; 05.06.01.0010.022473%Not Available
Diarrhoea07.02.01.001--
Diplopia17.17.01.005; 06.02.06.0020.014982%Not Available
Dizziness24.06.02.007; 17.02.05.003; 02.01.02.004--
Dyspepsia07.01.02.001--
Dysphagia07.01.06.0030.164803%
Dyspnoea22.02.01.004; 02.01.03.002--
Encephalopathy17.13.02.0010.029964%
Eosinophil count increased13.01.06.0040.014982%Not Available
Epilepsy17.12.03.0020.014982%Not Available
Fatigue08.01.01.002--
Feeling abnormal08.01.09.014--Not Available
Fracture15.08.02.001; 12.04.02.0010.029964%
Gastric cancer16.13.03.001; 07.21.02.0010.003908%Not Available
The 2th Page    First    Pre   2 3 4 5 6    Next   Last    Total 7 Pages